Mitomycin (Mutamycin)

General information

Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Anal cancer
• Bladder cancer
• Breast cancer
• Cervical cancer
• Cholangiocarcinoma
• Colorectal cancer
• Esophageal cancer
  • Esophageal adenocarcinoma
• Gallbladder cancer
• Gastric cancer
• Head and neck cancer

Diseases for which is was used

• Non-small cell lung cancer
• Pancreatic cancer

Patient drug information

• Mitomycin (Mutamycin) patient drug information (Chemocare)
• Mitomycin (Mutamycin) patient drug information (UpToDate)

History of changes in FDA indication

• 1974: Initial FDA approval for use in gastric and pancreatic carcinomas when combined with other chemotherapeutic agents.
• Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. (No supporting studies are cited)

History of changes in EMA indication

• 1962-10-05: EURD

Also known as

• Generic names: mitomycin-C, MTC
• Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin